Federal Register / Vol. 69, No. 207 / Wednesday, October 27, 2004 / Notices 62707

c. New Budget Period Program 

Proposed Activity Objectives. 

d. Budget. 

e. Measures of Effectiveness. 

f. Additional Requested Information. 

2. Financial status report, no more 

than 90 days after the end of the budget 

period. 

3. Final financial and performance 

reports, no more than 90 days after the 

end of the project period. 

4. At the completion of the project, 

the grant recipient will submit a brief 

summary 2,500 to 4,000 words written 

in non-scientific [laymen’s] terms. The 

narrative should highlight the findings 

and their implications for injury 

prevention programs, policies, 

environmental changes, etc. The grant 

recipient will also include a description 

of the dissemination plan for research 

findings. This plan will include 

publications in peer-reviewed journals 

and ways in which research findings 

will be made available to stakeholders 

outside of academia (e.g., state injury 

prevention program staff, community 

groups, public health injury prevention 

practitioners, and others). CDC will 

place the summary report and each 

grant recipient’s final report with the 

National Technical Information Service 

(NTIS) to further the agency’s efforts to 

make the information more available 

and accessible to the public. 

These reports must be mailed to the 

Grants Management Specialist listed in 

the ‘‘Agency Contacts’’ section of this 

announcement. 

VII. Agency Contacts 

We encourage inquiries concerning 

this announcement. 

For general questions, contact: 

Technical Information Management 

Section, CDC Procurement and Grants 

Office, 2920 Brandywine Road, Atlanta, 

GA 30341, Telephone: 770–488–2700. 

For scientific/research issues, contact: 

Paul Smutz, Ph.D, Project Officer, 

National Center for Injury Prevention 

and Control, Centers for Disease Control 

and Prevention (CDC), 4770 Buford 

Highway, NE. Mailstop K–02, 

Telephone: 770–488–1508, E-mail: 

wsmutz@cdc.gov.

For questions about peer review, 

contact: Gwendolyn Cattledge, Ph.D, 

Scientific Review Administrator, 

National Center for Injury Prevention 

and Control, Centers for Disease Control 

and Prevention (CDC), 4770 Buford 

Highway, NE., Mailstop K–02, 

Telephone: 770–488–1430, E-mail: 

gxc8@cdc.gov.

For financial, grants management, or 

budget assistance, contact: Nancy Pillar, 

Grants Management Specialist, CDC 

Procurement and Grants Office, 2920 

Brandywine Road, Atlanta, GA 30341, 

Telephone: 770/488–2721, E-mail: 

NFP6@cdc.gov.

VIII. Other Information 

This and other CDC funding 

opportunity announcements can be 

found on the CDC website, Internet 

address: www.cdc.gov. Click on 

‘‘Funding’’ then ‘‘Grants and 

Cooperative Agreements.’’

Dated: October 21, 2004. 

William P. Nichols, 

Acting Director, Procurement and Grants 

Office, Centers for Disease Control and 

Prevention.

[FR Doc. 04–24025 Filed 10–26–04; 8:45 am] 

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, 

National Center for Infectious Disease 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following committee 

meeting.

Name: Board of Scientific Counselors, 

National Center for Infectious Diseases 

(NCID). 

Times and Dates: 9 a.m.—5:30 p.m., 

December 9, 2004. 8:30 a.m.–2 p.m., 

December 10, 2004. 

Place: CDC, Auditorium B, Building 1, 

1600 Clifton Road, Atlanta, Georgia 30333. 

Status: Open to the public, limited only by 

the space available. 

Purpose: The Board of Scientific 

Counselors, NCID, provides advice and 

guidance to the Director, CDC, and Director, 

NCID, in the following areas: program goals 

and objectives; strategies; program 

organization and resources for infectious 

disease prevention and control; and program 

priorities. 

Matters To Be Discussed: Agenda items 

will include: 

1. Opening Session: NCID Update 

2. Futures Initiative Update 

3. Environmental Microbiology 

4. IT Consolidations/Bioinformatics Center 

5. Veterinary-Human Public Health Interface 

6. Global Disease Detection Initiative 

7. Topic Updates 

a. Influenza 

b. Pneumococcal Disease 

c. Genetics Initiatives 

8. Board meets with Director, CDC

Other agenda items include 

announcements/introductions; followup on actions recommended by the 

Board May 2004; consideration of future 

directions, goals, and recommendations. 

Agenda items are subject to change as 

priorities dictate. 

Written comments are welcome and 

should be received by the contact 

person listed below prior to the opening 

of the meeting. 

For Further Information Contact:

Tony Johnson, Office of the Director, 

NCID, CDC, Mailstop E–51, 1600 Clifton 

Road, NEO, Atlanta, Georgia 30333,

e-mail tjohnson3@cdc.gov; telephone 

404/498–3249. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry.

Dated: October 20, 2004. 

Alvin Hall, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention.

[FR Doc. 04–24024 Filed 10–26–04; 8:45 am] 

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Initial Review Group. Subcommittee 

A—Cancer Centers. 

Date: December 10, 2004. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Conference Centers, 5701 

Marinelli Road, North Bethesda, MD 20852. 

Contact Person: David E. Maslow, PhD., 

Scientific Review Administrator, Resources 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8117, 

Bethesda, MD 20892–7405, (301) 496–2330.

62708 Federal Register / Vol. 69, No. 207 / Wednesday, October 27, 2004 / Notices 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Causes and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS)

Dated: October 29, 2004. 

Laverne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–23975 Filed 10–26–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Initial Review Group. Subcommittee 

A—Cancer Centers, Cancer Center 

Applications. 

Date: April 7–8, 2005. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Bethesda North Hotel, 5701 

Marinelli Road, Bethesda, MD 20852. 

Contact Person: David E. Maslow, PhD, 

Chief, Resources and Training Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, 6116 Executive 

Boulevard—Room 8117, Bethesda, MD 

20892–8328, (301) 496–2330.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS)

Dated: October 19, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–23978 Filed 10–26–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in section 552b(c)(4) 

and 552b(c)(6), Title 5 U.S.C., as 

amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Cancer 

Institute Initial Review Group Subcommittee 

E—Cancer Epidemiology, Prevention & 

Control. 

Date: December 9, 2004. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Bethesda North Hotel, 5701 

Marinelli Road, Bethesda, MD 20852. 

Contact Person: Mary C. Fletcher, PhD, 

Scientific Review Administrator, Research 

Programs Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Boulevard, Rm 8115, Bethesda, 

MD 20892, (301) 496–7413.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS)

Dated: October 19, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–23979 Filed 10–26–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets of commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy.

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Special Emphasis Panel On Nutrition. 

Date: November 19, 2004. 

Time: 8 a.m. to 12 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton-Silver Spring, 8727 Colesville 

Road, Quorium Room, Silver Spring, MD 

20910. 

Contact Person: Judy S. Hannah, PhD, 

Scientific Review Administrator, Review 

Branch, Division of Extramural Affairs, 

National Heart, Lung, and Blood Institute, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 7190, Bethesda, MD 20892, 

(301) 435–0287.

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS)

Dated: October 14, 2004. 

LaVerne Y. Stringfield, 

Director, Office of Federal Advisory 

Committee Policy.

[FR Doc. 04–23980 Filed 10–26–04; 8:45 am] 

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee (5 U.S.C. 

Appendix 2), notice is hereby given of 

a meeting of the Board of Scientific 

Counselors, National Human Genome 

Research Institute.